Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data
Tue, 25 Jun 2024
2024年6月25日星期二
MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.
賓夕法尼亞州馬爾弗恩,2024年6月25日/美通社/ - Annovis Bio Inc.(紐交所:annovis bio)("Annovis"或"公司")是一家晚期臨床藥物平台公司,致力於開創變革性的神經變性疾病(如阿爾茨海默病(AD)和帕金森病(PD))療法,今天宣佈將舉辦投資者網絡研討會,討論其主導藥物候選Buntanetap的最新進展和未來計劃。
Investor Call Details:
投資者電話討論詳情:
- Date and Time: July 2, 2024, 4:30pm ET.
- Register Today: Webcast Registration
- 日期和時間:2024年7月2日,美東時間下午4:30。
- 今天就註冊:網絡研討會註冊
Topics to Be Covered:
將涵蓋以下話題:
- Recent advancements in the development of Buntanetap.
- Strategic plans for upcoming clinical trials.
- Overview of the company's progress and future direction.
- Buntanetap開發的最新進展。
- 即將到來的臨床試驗的戰略計劃。
- 公司進展及其未來發展方向概述。
Register Today: Investors and interested parties are encouraged to register for the webcast in advance. To register, please visit Webcast Registration and complete the registration form.
投資者和其他有興趣的方可預先註冊網絡研討會。請訪問X網站並完成註冊表格。網絡研討會註冊關於Buntanetap: Buntanetap(以前稱爲Posiphen或ANVS401)通過抑制多種神經毒蛋白的形成,包括澱粉樣蛋白β、tau、α-突觸核蛋白和TDP43,以改善突觸傳遞、軸索轉運和減少神經炎症,旨在逆轉AD、PD和其他神經退行性疾病的神經退變現象。
About Buntanetap: Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases.
關於Annovis Bio Inc.:總部位於賓夕法尼亞州的Malvern市,Annovis Bio公司專注於解決像AD和PD這樣的神經退行性疾病中的神經退化問題。該公司的創新方法針對多種神經毒性蛋白,旨在恢復大腦功能,並提高患者的生活質量。有關更多信息,請訪問Annovis Bio網站。
About Annovis Bio Inc.: Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company's innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Annovis Bio公司網站。www.annovisbio.com和我們一起LinkedIn, YouTube和grupo aval股票 和價值sa.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts
鼓勵感興趣的投資者和股東通過註冊電子郵件提醒來註冊以獲取新聞發佈和行業更新。https://www.Annovisbio.com/email-alerts
Forward-Looking Statements
前瞻性聲明
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
早期AD患者的有效性
Contacts
聯繫方式
Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Annovis Bio, Inc.
101 Lindenwood Drive
225套房
馬爾文,PA 19355
www.annovisbio.com
Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
IR@annovisbio.com
Investor Website
投資者聯繫方式
Scott McGowan
InvestorBrandNetwork(IBN)
電話:310.299.1717
IR@annovisbio.com
投資者網站
Source: Annovis Bio, Inc.
消息來源:annovis bio,inc.